Mostrando 3 resultados de: 3
Evaluation of racotumomab for the treatment of lung cancer: Meta-analysis of controlled trials of the CIM
ArticleAbstract: Racotumomab is a therapeutic cancer vaccine entirely developed in Cuba and licensed in the country fPalabras claves:immunotherapy, Non-small cell lung cancer, Oncological vaccines, Racotumomab, Vaccinal treatmentAutores:Alfonso S., Aliuska Frías, Ballesteros J., Carmen Elena Viada, Hernández M., Mabel Álvarez, Macías A.E., Martha M. Fors-López, Quintero J., Robaina M.Fuentes:scopusNimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusSafety of racotumomab in the treatment of patients with non-small cell lung cancer
ArticleAbstract: In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary toPalabras claves:Adverse events, Clinical trial, Non-small cell lung cancer, RacotumomabAutores:Carmen Elena Viada, Estevez D., Gastón Y., Macías A.E., Pérez Ruiz L.Fuentes:scopus